Healthcare & Medical Business Setup in India for Foreign Investors

Industry Overview: India's Healthcare Landscape

India's healthcare sector is one of the fastest-growing industries in the country, projected to reach US$638 billion by 2025 at a CAGR of 22%. The hospital market alone reached US$193.4 billion in 2025, with expectations to hit US$364.6 billion by 2034 at a CAGR of 7.3%. The sector's growth is driven by an ageing population, rising middle-class incomes, expanding health insurance coverage, and increased government healthcare spending under Ayushman Bharat.

Foreign investment has been a major catalyst for this growth. Between April 2000 and June 2025, the drugs and pharmaceuticals sector attracted FDI inflows of US$24.62 billion, while hospitals and diagnostic centres received US$12.25 billion, and medical devices drew US$3.96 billion. In Q1 2025 alone, healthcare witnessed 71 deals worth US$2.6 billion focused on speciality pharma, biotech, digital health, and CRAMS.

The Indian government's focus on healthcare infrastructure has intensified since the pandemic, with initiatives including the National Health Mission, Ayushman Bharat Digital Mission, and the PM-ABHIM scheme for strengthening health infrastructure in all districts.

FDI Policy & Entry Routes for Healthcare

India offers one of the most liberal FDI frameworks for healthcare, recognising the sector's critical importance:

Hospitals and Clinics

FDI up to 100% is permitted under the automatic route in the hospital sector. This covers multi-speciality hospitals, single-speciality hospitals, diagnostic centres, day-care surgical centres, and clinics. No prior government approval is required, making it straightforward for foreign investors to set up or acquire healthcare facilities.

Medical Devices

The manufacture of medical devices allows 100% FDI under the automatic route. This covers Class A through Class D devices as classified by CDSCO under the Medical Devices Rules, 2017. India's medical device market is estimated at US$14 billion and is expected to grow to US$50 billion by 2030.

Pharmaceuticals

For pharmaceutical manufacturing, FDI policy differs based on the project type:

• Greenfield projects: 100% FDI under the automatic route
• Brownfield projects: Up to 74% FDI under the automatic route; beyond 74% requires government approval

The distinction between greenfield (new) and brownfield (existing) pharma projects is crucial. Brownfield acquisitions beyond 74% trigger government scrutiny under Press Note 1 of 2014 to prevent potential supply chain disruptions. Beacon Filing's FDI advisory service can guide investors through both routes.

Telemedicine and Digital Health

Digital health platforms, telemedicine services, and health-tech startups are generally classified under IT/ITeS and allow 100% FDI under the automatic route. The Telemedicine Practice Guidelines 2020 (revised 2024) provide the regulatory framework for cross-border telehealth services.

Required Licenses & Regulatory Bodies

Healthcare is one of the most heavily regulated sectors in India. The licensing landscape involves central, state, and local authorities:

The Central Drugs Standard Control Organisation (CDSCO), headed by the Drug Controller General of India (DCGI), is the primary regulatory body for pharmaceuticals and medical devices. As of November 2025, CDSCO has mandated that all hospitals and health institutions must procure only those medical devices that hold a valid license from CDSCO or the State Licensing Authority (SLA).

The Clinical Establishments (Registration and Regulation) Act, 2010 has been adopted by most Indian states and mandates registration of all clinical establishments. Requirements include minimum infrastructure standards, qualified staff ratios, and record-keeping protocols.

Entity Structure Options for Healthcare

The choice of entity structure depends on the specific healthcare sub-sector and investment scale:

Private Limited Company (Recommended for Hospitals & Pharma)

A Private Limited Company is the most suitable structure for foreign-invested hospitals, pharmaceutical companies, and medical device manufacturers. It permits 100% foreign shareholding, offers limited liability, and is compatible with PLI scheme participation. All major hospital chains in India, including Apollo Hospitals, Fortis Healthcare, and Max Healthcare, operate through this structure.

Foreign Subsidiary

A foreign subsidiary is the preferred entry method for global healthcare companies. It provides operational independence while leveraging the parent company's brand, technology, and clinical protocols. The branch office vs. subsidiary comparison is essential reading for healthcare investors.

Joint Venture

Joint ventures with Indian healthcare providers are common in the hospital sector. This approach provides local market knowledge, established doctor networks, regulatory navigation experience, and existing infrastructure. Several global hospital chains have entered India through JVs before moving to wholly-owned operations.

LLP Structure

While LLPs can receive FDI under the automatic route, they are less common in healthcare due to the capital-intensive nature of the sector and limitations on foreign portfolio investment. LLPs may be suitable for healthcare consultancies, telemedicine platforms, or smaller clinical operations.

Tax Incentives & Government Schemes

The healthcare sector benefits from substantial government support through multiple schemes:

PLI Scheme for Medical Devices (INR 3,420 Crore)

This scheme provides a 5% incentive on incremental sales for domestic manufacture of high-value medical devices including Linear Accelerators, MRI machines, CT-Scans, Mammograms, C-Arms, and Ultrasound machines. As of October 2024, total investment of INR 33,534 crore has been realised, and incentives of INR 3,215 crore have been disbursed to 45 companies. The scheme runs through FY 2026-27.

PLI Scheme for Bulk Drugs (INR 6,940 Crore)

This scheme promotes domestic manufacturing of critical Key Starting Materials (KSMs), Drug Intermediates (DIs), and Active Pharmaceutical Ingredients (APIs) to reduce import dependence, particularly from China. It has supported 191 first-time API/KSM/DI manufacturers across 28 greenfield facilities. Production tenure extends to FY 2028-29.

PLI Scheme for Pharmaceuticals (INR 15,000 Crore)

With 55 approved applicants, this scheme has mobilised investments worth INR 40,294 crore (exceeding the target of INR 17,275 crore), supporting over 350 manufacturing units. Cumulative sales reached INR 3.08 lakh crore including INR 1.98 lakh crore in exports, while generating 97,000 jobs.

Medical Device Parks Scheme

The government has allocated INR 400 crore for setting up four medical device parks across India (Himachal Pradesh, Madhya Pradesh, Tamil Nadu, and Uttar Pradesh). These parks provide plug-and-play infrastructure, shared testing facilities, and streamlined approvals for medical device manufacturers.

Customs and Tax Benefits

Reduced or nil customs duty applies to life-saving medical equipment including cancer diagnostics and treatment devices, renal care products, and specified implants. New manufacturing companies benefit from an effective corporate tax rate of 17.16% under Section 115BAB.

Key Compliance Requirements

Healthcare companies face sector-specific compliance obligations beyond standard annual compliance:

CDSCO and Drug Regulatory Compliance

Pharmaceutical manufacturers must maintain Good Manufacturing Practices (GMP) compliance per Schedule M of the Drugs and Cosmetics Act. Medical device manufacturers must comply with the Medical Devices Rules, 2017, including quality management systems (ISO 13485), device classification, and post-market surveillance. Clinical trials require CDSCO approval and ethics committee clearance.

Clinical Establishment Standards

Hospitals must comply with minimum standards covering infrastructure (operating theatre specifications, ICU bed ratios, equipment lists), staffing (doctor-to-patient ratios, nursing requirements), record-keeping (EMR systems, patient consent protocols), and infection control protocols.

FEMA and RBI Reporting

Foreign-invested healthcare entities must file FEMA compliance reports including FC-GPR (share allotment), FC-TRS (share transfer), and the Annual Return on Foreign Liabilities and Assets. Healthcare companies with external commercial borrowings must comply with RBI ECB guidelines. Beacon Filing's FEMA/RBI compliance service handles these requirements.

Biomedical Waste Management

The Biomedical Waste Management Rules, 2016 (amended 2024) mandate segregation, collection, treatment, and disposal of biomedical waste through authorised Common Biomedical Waste Treatment Facilities (CBWTFs). Non-compliance can lead to penalties up to INR 5 lakh and imprisonment.

PCPNDT Act Compliance

Healthcare facilities offering prenatal diagnostics must comply with the Pre-Conception and Pre-Natal Diagnostic Techniques (PCPNDT) Act, including registration, record-keeping of all ultrasonography tests, and strict prohibitions on sex determination.

Data Protection

Health data is classified as sensitive personal data under India's Digital Personal Data Protection Act, 2023. Healthcare providers must implement enhanced security measures, obtain explicit consent for data processing, and comply with data breach notification requirements under the DPDP Rules 2025.

Setting Up Healthcare Operations in India

Here is a practical guide for foreign investors establishing healthcare operations in India:

Phase 1: Entity Setup and Approvals (2-3 months)

1. Incorporate a foreign subsidiary or Private Limited Company via MCA
2. Open a bank account and remit initial capital
3. File FC-GPR with RBI within 30 days of share allotment
4. Obtain GST registration and PAN
5. Apply for relevant state-level registrations

Phase 2: Facility Setup (6-18 months, varies by type)

1. Secure facility location and obtain building approvals
2. Apply for Clinical Establishment Registration
3. Obtain Fire Safety, Pollution Control, and Municipal NOCs
4. Apply for Drug License and Medical Device licenses as applicable
5. Set up biomedical waste management systems

Phase 3: Operational Launch (2-4 months)

1. Recruit medical and administrative staff
2. Procure and install medical equipment
3. Implement Hospital Information System (HIS) and EMR
4. Apply for empanelment with insurance companies (NABH accreditation helpful)
5. Obtain Atomic Energy Regulatory Board license if radiology services are offered

Typical Costs

Setting up a hospital typically requires 8-18 months including planning, construction, and licensing. Construction costs for a 50-bed hospital in metro cities range from INR 25-45 crore (approximately US$3-5.5 million), with per-bed costs averaging INR 50-90 lakh. Licensing and regulatory fees total INR 5-10 lakh. For smaller clinics or diagnostic centres, setup costs range from INR 50 lakh to INR 5 crore depending on speciality and location.

Beacon Filing provides end-to-end support through our India entry strategy service and registration checklist.

Emerging Opportunities and Future Outlook

India's healthcare sector presents several high-growth sub-segments that are attracting significant foreign investment:

Digital Health and Telemedicine

The digital health market in India is projected to reach US$37 billion by 2030. The Ayushman Bharat Digital Mission (ABDM) is creating a unified digital health infrastructure with Ayushman Bharat Health Accounts (ABHA) for all citizens. Foreign healthtech companies can enter through 100% FDI under the automatic route (classified under IT/ITeS). Telehealth platforms like Practo, 1mg (now Tata 1mg), and PharmEasy have demonstrated scalable business models with significant foreign backing.

Medical Tourism

India attracts over 2 million medical tourists annually, driven by cost advantages (procedures cost 60-90% less than in the US), world-class facilities, and English-speaking medical professionals. The medical tourism market is projected to reach US$13 billion by 2026. Foreign hospital chains can leverage this opportunity by establishing centres of excellence in cardiology, orthopaedics, oncology, and organ transplantation.

Medical Device Manufacturing

India currently imports 75-80% of its medical devices. The government's push for self-reliance through PLI schemes and medical device parks is creating substantial opportunities for foreign device manufacturers to set up local production, benefiting from lower manufacturing costs and proximity to a growing domestic market. The Make in India initiative specifically targets medical devices as a priority sector.

Ayurveda and Traditional Medicine

The global Ayurveda market is growing at 16% CAGR and India dominates production. Foreign investors interested in AYUSH (Ayurveda, Yoga, Unani, Siddha, Homeopathy) sector products benefit from 100% FDI under the automatic route and can access the recently established AYUSH export promotion framework. WHO recognition of traditional medicine has boosted international acceptance.

Case Studies: Major Foreign Players in Indian Healthcare

IHH Healthcare (Malaysia) / Fortis Healthcare

IHH Healthcare, Asia's largest private healthcare group based in Malaysia-Singapore, acquired a controlling 31% stake in Fortis Healthcare, one of India's largest hospital chains with 28+ hospitals and 4,500+ beds. This acquisition gave IHH access to India's premium healthcare market while leveraging Fortis's established network and brand recognition. The transaction was structured as a preferential allotment and open offer under SEBI regulations.

KKR (USA) / Max Healthcare

American private equity firm KKR backed Radiant Life Care, which merged with Max Healthcare to create one of India's largest hospital networks. As of 2025, Max Healthcare has the highest foreign institutional investor (FII) shareholding among listed hospital companies at approximately 51.8%, demonstrating the depth of foreign investor confidence in Indian healthcare.

Apollo Hospitals

While promoted by the Indian Reddy family (~35% shareholding), Apollo Hospitals has attracted significant foreign investment from institutional investors including BlackRock. Foreign institutional investors hold over 44% of Apollo's shares. Apollo operates 73+ hospitals with over 10,000 beds and is a model for how foreign capital and Indian healthcare expertise combine for scale.

Global Pharma and Medical Device Companies

Major global pharmaceutical companies operating in India include Pfizer, Abbott, AstraZeneca, Novartis, Roche, Johnson & Johnson, and Sanofi, all operating through wholly-owned Indian subsidiaries (Private Limited Companies with 100% foreign shareholding). Medical device leaders including Medtronic, Siemens Healthineers, GE Healthcare, and Philips have significant manufacturing operations in India, benefiting from PLI scheme incentives.

Frequently Asked Questions